French biotech Abivax announced positive phase 3 results for obefazimod, its orally available miRNA-124 enhancer for ulcerative colitis, achieving a 16.4% placebo-adjusted clinical remission at eight weeks. The trials involved 1,275 patients globally with moderate to severe disease. Safety profile remained favorable, with some transient headaches reported. A maintenance trial is ongoing with results expected in 2026. This positions obefazimod as a promising new oral treatment option within a growing inflammatory bowel disease market predicted to reach $30 billion by 2030.